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Abstract
Polycystic liver disease (PLD) is the result of embryonic ductal plate malformation of the intrahepatic biliary tree.
The phenotype consists of numerous cysts spread throughout the liver parenchyma. Cystic bile duct malformations
originating from the peripheral biliary tree are called Von Meyenburg complexes (VMC). In these patients embryonic
remnants develop into small hepatic cysts and usually remain silent during life. Symptomatic PLD occurs mainly in
the context of isolated polycystic liver disease (PCLD) and autosomal dominant polycystic kidney disease (ADPKD).
In advanced stages, PCLD and ADPKD patients have massively enlarged livers which cause a spectrum of clinical
features and complications. Major complaints include abdominal pain, abdominal distension and atypical symptoms
because of voluminous cysts resulting in compression of adjacent tissue or failure of the affected organ. Renal
failure due to polycystic kidneys and non-renal extra-hepatic features are common in ADPKD in contrast to VMC
and PCLD. In general, liver function remains prolonged preserved in PLD. Ultrasonography is the first instrument to
assess liver phenotype. Indeed, PCLD and ADPKD diagnostic criteria rely on detection of hepatorenal cystogenesis,
and secondly a positive family history compatible with an autosomal dominant inheritance pattern. Ambiguous imaging
or screening may be assisted by genetic counseling and molecular diagnostics. Screening mutations of the genes causing
PCLD (PRKCSH and SEC63) or ADPKD (PKD1 and PKD2) confirm the clinical diagnosis. Genetic studies showed that
accumulation of somatic hits in cyst epithelium determine the rate-limiting step for cyst formation. Management
of adult PLD is based on liver phenotype, severity of clinical features and quality of life. Conservative treatment
is recommended for the majority of PLD patients. The primary aim is to halt cyst growth to allow abdominal decompression
and ameliorate symptoms. Invasive procedures are required in a selective patient group with advanced PCLD, ADPKD or
liver failure. Pharmacological therapy by somatostatin analogues lead to beneficial outcome of PLD in terms of symptom
relief and liver volume reduction.
Keywords: Cystogenesis, Polycystic liver disease (PLD), Hepatomegaly, Biliary tract disease, Ductal plate
malformation (DPM), Von Meyenburg complex (VMC), Autosomal dominant polycystic liver disease (PCLD),
Autosomal dominant polycystic kidney disease (ADPKD)
Review
Disease name
Polycystic liver disease (PLD) is a collection of rare hu-
man disorders that result from structural changes in the
biliary tree development [1,2]. Genetic mechanisms and/
or signaling defects are the root cause of ductal struc-
tures to become separated from the biliary tree finally
resulting in cyst formation [2,3]. Typically, these discon-
nected biliary structures are present in a very early dis-
ease stage, but remain asymptomatic until cyst growth
initiates in adulthood [4].
Three PLD entities are recognized in adults. Von
Meyenburg complexes (VMC; biliary hamartoma; hep-
atic cystic hamartoma) with characteristic small, non-
hereditary nodular cystic lesions [ORPHA386] [4,5].
Isolated polycystic liver disease (PCLD; autosomal domin-
ant PLD) [OMIM#174050; ORPHA2924] with presence of
innumerable hepatic cysts and autosomal dominant
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polycystic kidney disease (ADPKD) [OMIM#173900;
OMIM#613095; OMIM#600666; ORPHA730] with cysts
in both kidneys and in many cases hepatic cysts.
This paper reviews the pathological and clinical features
of these 3 adult cystic disorders that share presence of nu-
merous hepatic cysts with an intact biliary tree architecture.
Definition
PLD is a rare inherited Mendelian disorder that is char-
acterized by development of multiple hepatic cysts. The
classification of PLD follows the histological changes
that are due to ductal plate malformation (DPM) during
fetal development [6,7]. Definitions of cystic malformations
are either based on the location of the affected (cilium-re-
lated) protein or follows radiological findings [8,9].
Ductal plate malformation
The biliary tree emerges from the endodermal hepatic
diverticulum [1]. Development of the biliary system
starts from the 8th week of gestation by formation of
single layered hepatoblasts surrounding the portal vein
(ductal plate). Duplication of ductal plate cells forms a
double layer that finally dilate to a tubular structure,
the primitive bile duct. Hepatoblast differentiation to a
biliary phenotype and tubulogenesis is stimulated by
the Notch, TGF-β and canonical Wnt signaling path-
ways [2]. Cell differentiation from hepatoblasts to cho-
langiocytes, tubule elongation and bile duct remodeling
are completed by 30 weeks of gestation. Intrahepatic and
extrahepatic bile duct systems are then merged and share
the hepatic hilum. During the first year of life intrahepatic
biliary epithelium maturates further [1,2,7]. PLD develops
as a result of ductal plate malformation. The stage that is
affected by faulty remodeling determines the phenotype.
For example, VMC is thought to result from embryonic
ductal involution at a late stage [7,10].
Bile duct formation requires a network of epithelial-
mesenchymal interactions, and presence of growth and
transcription factors to control appropriate cell migra-
tion, adhesion and cholangiocyte differentiation. Aber-
rant expression profiles and signaling result in deficient
remodeling, and subsequently abnormal dilated or dis-
connected ductal plate cells developing into biliary cystic
structures [3,11]. Recently, a new classification for DPM
has been proposed on the basis of Hnf-1β, Hnf-6 and
cystin-1 gene deficient mouse models. This classification
distinguishes 3 DPMs: 1) abnormal hepatoblast differen-
tiation, 2) failure of bile duct maturation, 3) perturbation
of ductal expansion [6].
Ciliopathy and cholangiopathy
Ciliopathies represent an emerging class of human disor-
ders that are caused by defects in distinct genes affecting
ciliary structures or function. They may be inherited as
simple recessive traits, but also in a dominant fashion.
Phenotypic expressivity is under the control of numer-
ous genetic modifiers [8]. Ciliopathies usually result in
shared clinical features, such as intellectual disability,
retinal defects and polydactyly, but the most well-known
phenotype is that of cystic kidneys [12]. The proteins af-
fected in ADPKD are located at the cilium which has led
to the classification of ADPKD as a ciliopathy [13]. By
contrast, the proteins associated with PCLD are not lo-
cated to the cilium. Hepatic cysts are lined by cholangio-
cytes and therefore the term cholangiopathy is used for
PCLD [3].
Radiology
Radiological imaging assists in classifying PLD. Detec-
tion of macroscopically hepatic and renal cysts is facili-
tated by ultrasonography, magnetic resonance imaging
(MRI) or computed tomography (CT)-scanning without
or with (creatinine-permitting) intravenous contrast ma-
terial [9]. On ultrasound, cysts appear as homogeneous
anechoic fluid-filled round spaces. MRI is superior over
ultrasound and CT, and allows better detection of small
cysts in young individuals [14]. This technique captures
biliary tree pathology and differentiates parenchym from
biliary tree (Figure 1).
Epidemiology
PCLD has a prevalence of 1/100,000 to 1/1,000,000 or
1- 9/100,000 (1/158,000 in The Netherlands), while the
prevalence of ADPKD ranges between 1/400 to 1/1,000
[13,15]. The incidence of VMC has been estimated up
to 1/18-1/145 or 7-60/1,000 (0.69-5.6%) depending on
the various autopsy studies [10,16].
Clinical description
Von Meyenburg complexes
VMC, also termed microhamartomas, are benign cystic
nodules scattered throughout the liver. They are usually
interlobularly located and at peripheral bile ducts below
the Glisson’s capsule [7]. VMC may occur isolated or in
the context of PCLD and ADPKD [4,11,17]. VMC are
frequently an incidental finding at radiological imaging,
surgery or autopsy studies.
Histologically, they are characterized by small embryonic
DPM remnants (<1.5-cm-diameter) or larger (small) hamar-
tomas (>1.5 cm) delineated by regular cuboidal epithelium
and embedded in fibrous stroma. Dilated structures initially
communicate with the peripheral intrahepatic biliary tree,
but separate with development [7,10].
VMC usually remain silent during life and require no
management or follow-up examination [17]. Although mild
liver test disturbances may be observed, significant hepato-
megaly or liver disease is rare in VMC. Incidentally, clinical
features of epigastric pain, fever, cholangitis and jaundice
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appear when communication of multicystic VMC with the
biliary tree cause biliary obstruction [18]. Episodes of liver
sepsis indicates antibiotic treatment and follow-up of liver
function tests. Abdominal pain and discomfort resolves with
time. The diagnosis of VMC can be confirmed by MRI.
Extra-hepatic features are absent.
PCLD and ADPKD
Hepatic cysts are the major clinical feature in PCLD and
the most frequent extra-renal manifestation in ADPKD
[14]. Cysts originate from medium-sized bile ducts. His-
tologically, they are delineated by cuboidal, flattened epi-
thelial cells surrounded by fibrous stroma [7].
Figure 1 Abdominal MRI and CT in patients with PLD. (A) Axial T1-weighted and (B) coronal T2-weighted MRI present 1 large cyst and numerous cystic
nodules scattered at peripheral bile ducts. (C-D) CT-scanning in a PCLD patient presents multiple cysts originating from medium-sized bile ducts. (E-F)
Co-occurrence of polycystic kidneys exists in ADPKD. Both PRKCSH and PKD2 gene mutations were predicted to be pathogenic (GRCh37-hg19; HGMD). Hepatic
cysts are indicated by white arrows. (G) Diffuse VMC present numerous small-sized hepatic cysts located at peripheral branches of the biliary tree (in green).
(H) The PLD phenotypes are arbitrarily staged and indicate disease progression. The disease course is progressive in a subset of severely affected PLD patients.
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They may be confined to 1 or more segments or
spread evenly throughout the liver. Presence of large and
numerous cysts frequently lead to hepatomegaly. One
study showed that the overall hepatic cyst prevalence in
ADPKD patients (age range15-46 years) is 83%, with the
highest prevalence of 94% in 35- to 46-year-old patients.
This corresponds with an increased prevalence of mul-
tiple hepatic cysts in older PLD patients [14].
The variable number, size, location and distribution of
cysts determines the spectrum of symptoms which is re-
lated to the extent of hepatomegaly [4]. Pain may ensue
mainly because of tension on Glisson’s liver capsule. Ab-
dominal discomfort, pyrosis, early satiety, weight loss
and anorexia may arise in advanced PLD [15,19]. Pa-
tients who have large hepatic cysts that exert pressure
on the stomach and displacement of other abdominal
organs are at risk for malnutrition and nutritional defi-
ciencies [20].
Females with ADPKD or PCLD usually have a more
severe liver phenotype, especially for those with a history
of multiple pregnancies and prolonged exogenous estro-
gen exposure [17,21,22]. Females have higher average
liver volumes, are younger at presentation and more sus-
ceptible to progressive PLD, suggesting a hormonal
component [14,15,19]. In general, patients with PCLD
have more severe symptoms and liver-related complica-
tions compared to ADPKD [23]. Hepatic cysts are rarely
present in young children, but in exceptional cases symp-
tomatic PLD may develop in young ADPKD patients.
The risk to develop severe PLD is independent from
the ADPKD genotype, but is related to the severity of
renal disease [13,23]. Here, presence of a PKD1 mutation
puts the patient at risk for an earlier onset and outcome
of renal disease compared to the PKD2 [24,25].
Hepatic complications in PCLD and ADKPD
Complications may occur due to massively hepatomeg-
aly or result from invasive treatment [15,19]. It has been
estimated that about half of the patients with advanced
hepatic disease have had cyst hemorrhage, cyst rupture
or a cyst infection [15,26]. These manifestations appear
to be more frequent in ADPKD compared to PCLD [27].
Here, we will discuss the clinical and diagnostic signs for
cyst hemorrhage, rupture, infection and other rare com-
plications in PCLD and ADPKD.
Hemorrhage
Intrahepatic cyst bleeding typically presents as acute
pain in the upper right-side of the abdomen. Symptoms
develop acutely, progress in the first day(s), but resolve
spontaneously. Sometimes, the nature of the abdominal
pain can be colicky and accompanied by vomiting. Ultra-
sonography may be helpful to assess features suggestive
for cyst bleeding such a higher attenuation value, aggregated
fibrin deposits and possibly internal septa of hematomas.
High signal intensity on MRI supports the diagnosis of an
intrahepatic cyst bleeding [9,28].
Infection
Cyst infections are a serious complication because of its
indolent course, demanding treatment and high risk of
recurrence. Current diagnostic criteria rely on clinical,
biological and radiological parameters including abdom-
inal tenderness, fever (>38°C for >3 days), an increased
C-reactive protein level and proven absence of spontan-
eous intra-cystic bleeding by CT-scanning. Hepatic cyst
wall thickening and heterogeneous fluid (debris) are
suggestive for infection. The diagnostic accuracy of
MRI is unknown and CT-scanning has a low sensitiv-
ity and specificity to identify cyst infection [29]. 18 F-FDG
positron emission tomography (PET)-imaging technique
is preferable to detect the exact location of the infected
lesion(s) [29].
PLD patients may have strongly elevated CA19-9
levels [30]. Extremely high CA19-9 levels were found in
episodes with hepatic cyst infection and declining during
recovery [31]. Detection of neutrophils and infectious
agent(s) in the cyst fluid aspirate confirms the cyst infec-
tion and indicative for targeted antibiotic treatment [29].
Rupture
Cyst rupture is an exceptional rare complication and
presents with acute onset of pain. Hemodynamic com-
plications are rare, but have been reported in the litera-
ture [32]. Abdominal discomfort from prolonged ascites
and increased cyst volume needs stringent follow-up. If
intra-peritoneal (blood) fluid leakage persists, a surgical
intervention is inevitable for hemostasis control [28].
Portal hypertension and ascites
In advanced stages there are 2 processes that may lead
up to portal hypertension. First, there is reduction of
hepatic vein outflow. Secondly, portal vein inflow may
be compressed in advanced disease due to the volume
effect of cysts.
Signs of hepatic vein outflow obstruction (HVOO) are
abdominal pain, hepatomegaly and transudative ascites
(90-96%) [33]. Hepatic vein thrombosis is commonly
recognized as the cause of HVOO, and case series re-
ported also the Budd-Chiari syndrome secondary to
PLD [33,34]. The survival of hepatic vein thrombosis is
low in severe cases [35]. Mechanical pressure symptoms
of hepatomegaly may extend from hepatic veins to junc-
tions with the vena cava inferior (IVC). Compression of
IVC is characterized by increased renal outflow pressure
that provokes development of ascites and edema in the
lower extremities [36].
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In addition, hepatic cysts may cause a compromised
portal venous flow [37]. These abovementioned compli-
cations lead to development liver fibrosis. Secondary
complications of portal hypertension are the result of se-
vere liver fibrosis such as esophageal varices, splenomeg-
aly and transudative ascites may develop, but advanced
fibrosis is a rare event [26]. Typically these features are
seen in the elderly. In addition, lymphatic leak and chronic
renal disease may contribute to development of ascites in
severe PLD patients [33,37].
Jaundice
Portal hypertension may be accompanied by other signs
of hepatic failure such as jaundice [38]. Although jaun-
dice is usually seen in advanced stages, it may occur at
any stage. An uncommon cause of jaundice is obstruc-
tion of the intrahepatic or extrahepatic bile ducts by
hepatic cysts [26]. Recurrent cholangitis is a rare compli-
cation of this condition [34].
End-stage liver disease
Progression to end-stage liver disease usually results in
the context of extremely increased liver volumes. Liver
failure is seen incidentally, usually in a very late stage of
the disease [15,19]. Symptomatic patients with hepato-
megaly (severe PLD) frequently do not meet the Model
for End-Stage Liver Disease (MELD). Therefore, MELD
exception criteria including assessment of malnutrition
and quality of life are used [20]. Liver transplantation
has excellent survival rates (>90% at 5 year) [39,40].
Extra-hepatic manifestations
Kidney
The main differentiating feature between PCLD and
ADPKD is the presence of polycystic kidneys. While
this is the primary lesion in ADPKD, renal disease is
absent in PCLD [27]. Disease progression depends on
genotype, but also on environmental factors [25]. The
majority of adult ADPKD patients develop enlarged
kidneys and end-stage renal disease. In contrast, few
renal cysts may be present in 28-35% of PCLD pa-
tients, but renal failure does not occur [15,19].
In contrast to PCLD, ADPKD is a multi-systemic dis-
order. Hypertension is one of the first signs of renal
disease development and is related to progressive kid-
ney enlargement and loss of renal function [41,42]. It
is still unclear whether early anti-hypertensive treat-
ment prevents renal function decline [43]. The most
common feature is abdominal/flank pain due to pres-
sure symptoms and stretching of the renal cyst wall.
ADPKD patients are also at-risk for other renal com-
plications such as hematuria, urinary tract infections
and kidney stones [21,41].
Cardiovascular system
ADPKD patients may develop hypertension, intracranial
aneurysms (ICA), arterial aneurysms and several cardiac
valvular abnormalities [44]. Early assessment of cardio-
vascular risk factors in ADPKD is advised, especially in
young ADPKD patients [45,46].
Mitral valve prolapse has a higher prevalence in
ADPKD up to 25–41.2% compared to 0–10.5% in PCLD
[19,27,47,48]. Other important connective tissue abnor-
malities such as aortic root dilatation and abdominal aorta
aneurysm (AAA) have been reported in ADPKD [49]. If
the family history is positive, screening of unaffected fam-
ily members by MR-angiography is recommended [50,51].
Non-renal extra-hepatic cysts
The phenotype of PCLD is mainly restricted to the liver.
Extensive radiological imaging of ADPKD patients have
demonstrated that there are cysts in other abdominal or-
gans such as the pancreas (9%) or seminal vesicles of the
testis (43%) [52,53]. These cystic manifestations symp-
tomatically silent.
Arachnoid cysts is central nervous system manifest-
ation that is seen in 8% of ADPKD patients. This condi-
tion may occasionally lead to a subdural hematoma [50].
Abdomen
Abdominal wall hernias may be present in PLD patients.
Clinical series have suggested that (para)umbilical and
inguinal hernias may be seen in up to 15-45% of ADPKD
patients which may be explained by chronic compres-
sion due to high liver and kidney volumes [27,41,54].
Early reports have suggested a higher prevalence of co-
lonic diverticuli in PLD, but upon scrutiny there was
no evident association or increased risk for diverticular
disease [27,55].
Etiology
Germline mutation
Genetic analyses of both PCLD genes PRKCSH [OMIM*177060]
and SEC63 [OMIM*608648] may confirm the clinical
diagnosis and differentiate it from other PLD (Table 1)
[56-58]. These genes encode for the (glyco)proteins hepa-
tocystin and Sec63p [59]. Both proteins are located within
the endoplasmic reticulum (ER) and are responsible for
quality control and translocation of glycoproteins into
the ER [60]. Since about 16-22% of PCLD patients
harbor a pathogenic variant, PCLD is assumed to be
genetically heterogeneous and other loci should be
nvolved. There is no clear genotype-phenotype associ-
ation [15,61].
Mutations in the PKD1 gene [OMIM*601313] or
PKD2 gene [OMIM*173910] are responsible for renal
cyst initiation in >90% of the cases [62]. Several
ADPKD families possess no mutations on PKD1 or
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PKD2 [67,68]. It is hypothesized that these cases are
linked to another (yet unidentified) PKD3 gene
[OMIM*600666] [69]. PKD1 gene carriers have a
higher prevalence of hypertension, complications and
a higher risk of progressive renal failure compared to
PKD2. Renal failure occurs at a much earlier age in
PKD1 carriers compared to PKD2 carriers [41].
Second-hit hypothesis
PLD patients have a heterozygous germline mutation and
it is hypothesized that cysts arise through functional loss
of the second allele [59]. This is the rate-limiting step in
the formation of cysts. Secondary, somatic hit mutations
have been identified in PKD1 or PKD2 genes in liver and
kidney tissues from ADPKD patients [70,71]. Similarly,
Table 1 Genetic and diagnostic determinants of PCLD and ADPKD
Polycystic liver disease(PCLD) Autosomal dominant polycystic
kidney disease (ADPKD)
Reference
Genotype
Cytogenetic gene location
(mutation frequency%)
Chr.19p13.2: PRKCSH (15%) Chr.16p13.3: PKD1 (75.7%) [62,63]
Chr.6q21: SEC63 (5.7%) Chr.4q21: PKD2 (13.4%)
Mutation (type; N,%) 25 PRKCSH 22 SEC63 980 PKD1 193 PKD2 [HGMD]
missense 4 (16%) 6 (27.3%) 250 (25%) 29 (15%)
splice site 4 (16%) 3 (13.6%) 77 (7.8%) 32 (16.6%)
insertion/deletion 10 (40%) 7 (31.8%) 440 (45%) 80 (41.5%)
indel 1 (4%) - 13 (1.4%) 7 (3.6%)
nonsense 6 (24%) 6 (27.3%) 202 (20%) 45 (23.3%)
complex rearrangement - 8 (0.8%) -
Gene product; protein localization Cholangiopathy Ciliopathy [13,60]
Hepatocystin/ glucosidase II-β
subunit; ER
Polycystin-1 (TRPP1); primary cilium,
tight junction, extracellular matrix, ER
Translocation protein SEC63
homolog;
Polycystin-2 (TRPP2); primary cilium,
tight junction, extracellular matrix, ER
ER, membrane complex
Protein function Proper protein folding and protein
quality control
PC-1 and PC-2 form a mechanosensor
complex on the primary cilium
[13,60]
Posttranslational protein transport PC-1 for signaling detection, PC-2 is a
TRP channel for calcium influx
Predominant phenotype
Liver features Positive family history with: Most common extra-renal manifestation: 83%
with a polycystic liver (>20 hepatic cysts)
[14,64]
PCLD diagnostic criteria:
Clinical practice: <40 years and ≥1 hepatic cyst
≥40 years and ≥4 hepatic cysts
30-70 years and polycystic liver
(>20 hepatic cysts)
Kidney features Incidental finding without renal
disease: 28-35% with renal
cystogenesis
Positive family history with unknown
genotype:
[15,19,65,66]
ADPKD diagnostic criteria:
15-39 years and 3 renal cysts#
40-59 years and 2 renal cysts*
≥60 years and 4 renal cysts*
Negative family history:
<30 years and 5 renal cysts$
30-60 years and 5 renal cysts$
>60 years and 8 renal cysts$
Description of the data: A detailed overview of genotype characteristics and diagnostic criteria for PCLD and ADPKD phenotype assessment.
# unilateral or bilateral.
* in each kidney.
$ bilateral.
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loss-of-heterozygosity of the PRKCSH or SEC63 allele is
present in PCLD cyst tissues. This is fitting with the
second-hit-model for tumorgenesis which dictates that
the combination of a germline and somatic mutations
result in inactivated protein in target tissues [72,73].
Modifier genes and environmental factors
Mouse models suggest that additional genes may lead to
hepatic and renal cystogenesis [6]. It has been shown
that HNF-1β mutations affect disease progression and
outcome in ADPKD [25,74].
Once a cyst have been formed, progression to clinical
significant disease requires other mechanisms [8]. Cyst
fluid contains serum proteins but also cytokines and
growth factors which contribute to cyst formation [75,76].
Expression of estrogen hormone receptors in cyst epithe-
lium may trigger growth advantages [77].
Diagnosis
VMC is a radiological diagnosis [9,10]. Ultrasonography
shows multiple hyperechoic areas in the subcapsular re-
gion. The comet-tail sign is a special form of reverber-
ation artifact in detection of small cysts. This sign appears
as a trail on the image if small calcific or highly reflective
foci are interrogated on ultrasound [5]. MRI is preferred
above CT-scanning as it readily shows multiple hyperin-
tense focal lesions on T2-imaging [9].
Current diagnostic criteria in PCLD and ADPKD rely on
the age-related cystic liver phenotype with a positive family
history of autosomal dominant inheritance (Figure 2)
[64-66]. Ultrasonography of the liver and kidneys is usu-
ally the first modality used to assess a cystic phenotype.
The unified Ravine criteria for diagnosis of ADPKD relies
on counting the number of renal cysts in at-risk individ-
uals [65,66].
A single laboratory test that is of discriminative value for
PLD is lacking. The synthetic liver function is usually pre-
served in PLD. Mild elevations of γ-glutamyltransferase
sometimes combined with elevated alkaline phosphatase
values may be detected [15,19].
Differential diagnosis
PLD is a non-communicating biliary tree disorder and
should be differentiated from other neoplastic, infectious
and traumatic conditions [4]. The diffusion and variable
small-sized hyperechoic structures in VMC are import-
ant to differentiate from hepatic metastasis or microab-
cesses [9].
In general, differentiation from communicating biliary
tree disorders is important for management and progno-
sis. Bile duct ectasias or cystic dilatations belong to con-
nected intrahepatic cystic diseases. These features are
detected in ARPKD, Caroli disease (CD) and Caroli syn-
drome (CS). PLD is characterized by intrahepatic dis-
ease, a more late onset of disease in adulthood and
absence of congenital hepatic fibrosis (CHF).
Autosomal recessive polycystic kidney disease
Young and adult ADPKD patients are difficult to distin-
guish with other hepatorenal fibrocystic diseases such as
Figure 2 Comprehensive algorithm for diagnosis, management and genetic counseling in PCLD and ADPKD. The diagnostic criteria for
PCLD and ADPKD compromises family history and age-related liver or kidney phenotype respectively [64,66]. PLD therapy is individually decided
according to number, distribution and size of hepatic cysts [78]. Genetic counseling has an important role in symptomatic individuals with a
positive family history for hepatic and/or renal cystogenesis in order to differentiate PLD and clinical management.
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ARPKD and other ciliopathies [8]. ARPKD has an inci-
dence of 1/20,000 live births (ORPHA731; prevalence of
1.2/100,000) and a high peri-natal lethality. The pre-
dominant phenotype includes perinatal renal cysts and
CHF [12]. Presence of cystic dilatation of intrahepatic
biliary tree may be confused with disconnected hepatic
cysts [17]. The gene product polyductin is located at
the primary cilium suggesting molecular similarities
with the ciliopathy ADPKD [8].
Caroli disease and Caroli syndrome
CD is characterized by saccular, cystic dilations of the
more larger intrahepatic biliary system. In CS large
and small intrahepatic bile duct ecstasies are accom-
panied with CHF. CS has been typically associated with
renal disease as in ARPKD [7]. The incidence of CD is
approximately 1/1,000,000 births, but CS is more fre-
quent (ORPHA53035; ~250 cases). Both ARPKD and
CS have an autosomal recessive inheritance pattern
[12].
Genetic counseling in PCLD and ADPKD
Both PCLD and ADPKD have an autosomal dominant
inheritance pattern and the recurrence risk is 50%. Gen-
etic studies indicate an evident inter-familial clinical het-
erogeneity in PLD disease course among similar-aged
patients. Secondly, intra-familial studies suggested a
considerable phenotypic variability of hepatic cysts
(Figure 3). Clinical asymptomatic or undiagnosed mem-
bers contribute to underestimation of the actual disease
prevalence [24,41,61]. It is estimated that the penetrance
is ~80% [63].
These considerations raise the question whether it
is appropriate to screen members or children at-risk.
Counseling should include discussion about insurance,
employment and psychological factors. Genetic coun-
seling is recommended in severely affected PLD and
Figure 3 Intra-familial clinical heterogeneity in PCLD. Description of the data: (A) Pedigree of a PCLD family with PRKCSH gene mutation
c.374_375delAG in affected individuals. The index patient (*) has 4 members with symptomatic PLD. Although the family history is positive, family
members frequently are asymptomatic carriers or the liver phenotype remains unknown. (B) Axial CT-scanning, abdominal ultrasonography or
MRI in 4 PCLD patients presented a variably number of hepatic cysts without renal disease.
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Table 2 Determinants and recommendations in severe PCLD and ADPKD
Polycystic liver disease (PCLD)
Organ Determinant Recommendations
Liver Female sex Stop exogenous estrogen use in female patients [78]
Aging [21,22] Advise alternative contraceptive strategies
Environmental factors associated with PLD disease course [21,22]:
-Prolonged oral/exogenous female steroid use: estrogens,
contraceptive pill or (post-menopausal) hormonal replacement
therapy
-Multiple pregnancies
Brain Similar recommendations seem appropriate for patients with
isolated ADPLD, but more studies are required [19,79]
Indiscriminate screening is not recommended at present [44]
Heart Similar as in the general population [47] No recommendations
Autosomal dominant polycystic kidney disease (ADPKD)
Organ Determinant Recommendations
Kidney Environmental factors associated with renal cyst growth [83]: Avoid (excessive) caffeine administration and nephrotoxic agents
-caffeine Smoking cessation
-smoking
Influencing factors for renal cystogenesis [43,45]: Hypertension [43,45,46,81]:
-hypertension (≤35 years) - renal infection -Routinely standardized blood pressure measurement
-proteinuria - total kidney volume
-hematuria (<30 years) - male sex -Elektrocardiogram in hypertensive patients for LVH assessment
-urinary tract infection - low birth weight
-kidney stones - aging -Plasma LDL cholesterol control; urinary albumin excretion; left
ventricular mass index calculation
-Angiotensin converting enzyme inhibitors and/or angiotensin
receptor blockers
Dietary protein and salt restriction
Sufficient daily fluid intake
PKD1 gene mutation have a more severe disease course and earlier
onset of end-stage renal disease compared to PKD2 carriers [41]
Molecular diagnostics [24]
Liver Female sex Stop exogenous estrogen use in female patients [78]
Aging [21,22] Advise alternative contraceptive strategies
Environmental factors associated with PLD disease course [24,25]:
-prolonged oral/exogenous female steroid use: estrogens, contraceptive
pill or (post-menopausal) hormonal replacement therapy
-multiple pregnancies
Renal function/glomular filtration rate [23]; in particular females [43]
Brain Patients at risk: Patients with reasonable estimated life expectancy: periodic
3–5 years MR/CT-angiography screening [51]
-positive family history of (ruptured) ICA or stroke <50 years old
-previously ruptured ICA Surveillance/rescreening after negative results in patients with
a positive family history: 5–10 years (high-to low-risk) [13,81]
-warning symptoms: unusual headaches
-high-risk occupation (for example: airline pilot)
preparation for major elective surgery (for example: kidney
transplantation) [13,51]
Smoking cessation
Blood pressure control
The position of the mutation in PKD1 is predictive for development of
intracranial aneurysms [80] Hyperlipidemia control [51]
Molecular diagnostics [80]
Heart Screening is indicated [13,45]: Echocardiography [13,45]
-a murmur or systolic clicks are detected on examination
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may afford differentiation between ADPKD and PCLD
[8,12].
Molecular diagnostics may assist the counseling process
to establish a firm diagnosis in symptomatic patients and
families. In particular ADPKD, determination of the re-
sponsible gene is useful for those who are at-risk in
order to develop a strategy to prevent severe progres-
sive disease events or complications [80]. If the family
history for ICA is positive in an ADPKD family, screening
of unaffected family members by MR-angiography is rec-
ommended [50,51,81]. Counseling or genetic testing is not
advised in asymptomatic children [79].
Table 2 Determinants and recommendations in severe PCLD and ADPKD (Continued)
-positive family history of thoracic aorta dissection
Aorta ADPKD patients receiving hemodialysis [49] AAA: routine screening of the aortic size, using CT or abdominal
ultrasonography [49]
Similar as in general population for AAA [81]: 1-time screening with abdominal ultrasonography [81]
-Male between the ages of 65–75 and smoked >100 cigarettes
in a lifetime
-Male >60 years and a family history of AAA
This scheme indicates distinct factors that are related to physical health and disease progression in PCLD and ADPKD patients. These clinical elements listed per
organ may be valuable for consideration in management. Patients’ mental condition and health-related quality of life should be assessed by standardized
evaluation of symptoms in all PLD patients [82].
Figure 4 Indications and considerations for treatment strategies in symptomatic PLD. Schematic overview of relevant indications and
considerations in PLD management. Patient characteristics and liver phenotype such as severity of clinical symptoms, age, (surgical) history,
degree of hepatomegaly, and number, size and location of hepatic cysts are essential parameters for this decision. In general, the choice of
procedure is an individual process in consultation with the patient. Severely affected individuals are patients with massive hepatomegaly,
refractory symptoms, PLD-related complications and/or end-stage liver failure. Care and follow-up of these patients should be managed with
caution. *Notification: Results about treatment efficacy of prolonged or long-term somatostatin analogue use is unknown. **Arbitrary total
liver volume (TLV), because this outcome measurement is related to other parameters such as height, total body surface and sex. ***For example:
recurrent hepatic cyst infection, HVOO.
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Management and prognosis
VMC is an asymptomatic condition without long-term
consequences and treatment is not warranted. The pri-
mary aim of PLD therapy is to reduce symptoms by cur-
tailing hepatic cyst development. The treatment of choice
is driven by individual complaints [40]. Although the pri-
mary outcome measurement of PLD management is liver
volume, assessment of symptoms associated with quality
of life is an element for focus [82]. Therapeutic interven-
tions are not warranted in asymptomatic patients.
The first advice in PCLD and ADPKD is to stop oral
anticonceptives [20,78]. Although not formally investi-
gated, the use other (non-systemic) contraceptives such
as an intra-uterine device may be an acceptable alterna-
tive. Other guidelines are presented in Table 2 [81,83].
Supportive management with analgesics is the first-line
treatment in patients with acute or chronic abdominal
pain and tenderness.
The different invasive approaches with possible benefi-
cial outcomes in independent studies include aspiration
sclerotherapy, laparoscopic cyst deroofing or liver trans-
plantation [39,40,84]. Current indications and consider-
ations for invasive treatment are presented in Figure 4.
Treatment of portal hypertension and ascites are not
different from that in patients with other causes. In a se-
lected patient group were invasive procedures such as a
vascular or bile duct stent placement optional for de-
compression of the portal vein, inferior vena cava or bile
duct, or in HVOO treatment [37,85]. In general, man-
agement of vascular and bile duct complications due to
hepatic cystogenesis consists of relieving the obstruction
in order to improve venous and biliary drainage [26,35].
Although no concise guidelines are available, stents may
give temporal symptom relief of portal hypertension, as-
cites and jaundice. A porto-systemic shunt may be indicated
in presence of acute thrombosis or vascular compression to
establish patent hepatic and portal venous flow, but should
be weighed against possible complications. The primary aim
is to ameliorate symptoms by cyst decompression in these
advanced cases. This is often achieved by final treatment
strategies including liver resection, hepatic fenestration
procedures or liver transplantation [33].
Recent development of pharmacological options opened
up new treatment strategies for severe PLD patients.
Long-term follow-up studies with somatostatin analogues
demonstrated that these agents consistently lower total
liver volume in PLD patients [86,87]. A recent meta-
analysis reported that somatostatin analogues is particu-
larly effective in young females [88].
Conclusion
PLD compromises a clinically heterogeneous liver
phenotype identified in VMC, ADPKD and PCLD pa-
tients. Massively enlarged livers are present in a subset
of ADPKD and PCLD. Genetics and environmental fac-
tors such as exogenous estrogen intake and number of
pregnancies contribute to disease progression. A consider-
able intra-familial variability in liver phenotype and extra-
hepatic features makes screening modalities uncertain in
PCLD. Evaluation of PLD-related symptoms and quality of
life are necessary to decide beneficial management.
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